Holen Sie sich die Stockscreener-App
7.73
28.19%
1.70
Handel nachbörslich:
7.73
Omeros Corporation Aktie (OMER) Neueste Nachrichten
Omeros nears resubmission of narsoplimab BLA - Investing.com India
Omeros stock soars to 52-week high, hits $7.53 - Investing.com
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Business Wire
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
Omeros Q3 2024Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns (OMER) - Seeking Alpha
Data Storage Corporation Reports 2024 Third Quarter Financial Results and Provides Business UpdateWASHINGTON, D.C. – Data Storage Corporation (NASDAQ: DTST) released its financial results for the third quarter ending September 30, 2024, and provi - Defense World
SigmaTron International, Inc. Announces Departure and Appointment of Chief Financial OfficerUNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________FORM 8-K_______________CURRENT REPORTPurs - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
Sydney high school parents vent frustration at plan for single-sex schools to become co-educational - ABC News
Omeros (NASDAQ:OMER) Upgraded at RODMAN&RENSHAW - MarketBeat
United States shares lower at close of trade; Dow Jones Industrial Average down 0.47% - Investing.com India
Omeros stock soars to 52-week high, hits $5.68 By Investing.com - Investing.com Canada
Earnings call: Omeros narrows Q3 loss, progresses key drug programs By Investing.com - Investing.com Australia
Earnings call: Omeros narrows Q3 loss, progresses key drug programs - Investing.com India
Omeros (OMER) Stock Rises After Reporting Q3Results - Stocks Telegraph
Omeros Shares Hit 52-Week High on Plan to Resubmit Narsoplimab Application - MarketWatch
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
Rodman & Renshaw sets $9 target on Omeros stock with Buy rating - Investing.com
Omeros' (OMER) "Neutral" Rating Reiterated at Cantor Fitzgerald - MarketBeat
Omeros stock soars to 52-week high, hits $5.68 - Investing.com
500: Something went wrong - Investing.com UK
U.S. Stock market top gainers: AgEagle Aerial Systems surges by 151.55% while Gaxos.ai Inc gains 47.58% in ealry trading - Business Upturn
Needham & Company LLC Reaffirms "Hold" Rating for Omeros (NASDAQ:OMER) - MarketBeat
Omeros initiated with a Buy at Rodman & Renshaw - TipRanks
Omeros (NASDAQ:OMER) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Omeros: Q3 Earnings Snapshot - New Haven Register
Omeros Corporation Reports Third Quarter 2024 Financial Results - BioSpace
Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments - Yahoo Finance
Omeros Corporation Q3 2024 Financial Results Reviewed - TipRanks
Omeros up 4% as Q3 results beat on EPS - MSN
Omeros reports Q3 EPS (56c), two estimates (70c) - TipRanks
Q3 2024 Omeros Corp Earnings Call Transcript - GuruFocus.com
Omeros Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Omeros Q3 Loss Narrows to $32.2M, Advances Key Drug Programs Amid FDA Talks | OMER Stock News - StockTitan
Blackline, Inc. Appoints Philippe Omer Decugis as Senior Vice President for Europe - Marketscreener.com
Earnings Outlook For Omeros - Benzinga
Omeros (OMER) Set to Announce Earnings on Wednesday - MarketBeat
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 - Business Wire
Week Ahead In Pharmaceuticals: 5 Stocks To Watch (OMER, BOLD, XLRN...) - RTTNews
Omeros (NASDAQ:OMER) Stock Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Cardiff City board to hold meeting with Omer Riza this weekend - Wales Online
Atypical Hemolytic Uremic Syndrome Drugs Market 2034: - openPR
NVIDIA Co. (NASDAQ:NVDA) Stock Holdings Increased by Alpha DNA Investment Management LLC - Defense World
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving AverageHere's Why - MarketBeat
Focal Segmental Glomerulosclerosis Drugs Market Report 2024FSGS Drugs Market Size - WhaTech
Global Atypical Hemolytic Uremic Syndrome (aHUS) Treatment Market to Reach USD 2308.84 Million by 20 - PharmiWeb.com
Zaltenibart Receives FDA Rare Pediatric Disease Designation for C3 Glomerulopathy - Pharmacy Times
OMEROmeros Corporation Latest Stock News & Market Updates - StockTitan
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy - Business Wire
Global Alcohol Use Disorder Treatment Market to Reach USD 1,300 million by 2033 at a 6.4% CAGR, Driv - PharmiWeb.com
Omer Riza wants 'clarity' over Cardiff City manager position exactly one month on from Bulut sacking - Wales Online
Ischemia Reperfusion Injury Therapeutics Market Generated - openPR
Next Cardiff City manager latest as Omer Riza now favourite for job - Wales Online
Omer Arbel Office unveils planned community for Washington State site - The Architect's Newspaper
OMER (Omeros) Operating Margin % : 0.00% (As of Jun. 2024) - GuruFocus.com
Omer Riza admits pressure over Cardiff City job uncertainty as he reveals January transfer planning - Wales Online
Omer Arbel reflects on 20 years of ‘making materials uncomfortable’ to generate novel forms - Wallpaper*
PDE Inhibitors Market: Report Trends and Future Forecast Until (2024-2034) - IndiaPolitics.com
0.93%
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):